Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma

Melanoma Clinical Trial

Official title:

Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05714371
• Other study ID #: CTMT212AUS57
• Status: Completed
• Start date: October 2, 2021
• Est. completion date: January 27, 2022

Study information

• Verified date: January 2023
• Source: Novartis
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This was a retrospective cohort study using the PharMetrics database. The analysis was conducted using the most recent 5 years of data from the database, January 1, 2015, to October 30, 2020. Included patients were followed for outcome evaluation from the index date (first prescription of treatment, immunotherapy [IO], or targeted therapy [TT] following diagnosis of non-metastatic malignant melanoma and evidence of first lymph node resection), until the first occurrence or end of continuous eligibility or end of the study period.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 618
• Est. completion date: January 27, 2022
• Est. primary completion date: January 27, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria

• Patients with at least one diagnosis of malignant melanoma of skin anytime from the start of data collection until the start of study period.

• Patients with a procedure of first lymph node dissection or nodal basin ultrasound surveillance, per the National Comprehensive Cancer Network (NCCN) guidelines version 2.2020. The first lymph node dissection / nodal basin ultrasound surveillance signified that the patient was eligible to receive systemic treatment as adjuvant therapy.

• The first lymph node dissection or nodal basin ultrasound surveillance (index adjuvant date) must have had a diagnosis of malignant melanoma of skin within 6 months, to ensure that the dissection was related to melanoma.

• Patients with at least pharmacy or medical claim for the study drugs within 1 year on and after index date. The index date was the date of first prescription of study drug, IO (i.e., nivolumab, ipilimumab + nivolumab, pembrolizumab) or dabrafenib + trametinib.

• At least 18 years of age at the time of adjuvant treatment initiation.

• Patients with at least 6 months of continuous enrollment prior to the index date.

• Patients with at least 6 months of continuous enrollment after the index date.

• If necessary, there were additional criteria of absence of secondary malignancy (including metastatic site).

Exclusion Criteria

• Patients with a diagnosis of non-melanoma primary malignancy during the 6 months pre-index period.

• Patients with chemotherapy or interferon alpha before index date.

• Patients with pregnancy any time during the study period.

Related Conditions & MeSH terms

• Melanoma

Intervention

Drug:
• Nivolumab
Patients receiving nivolumab
• Ipilimumab + nivolumab
Patients receiving ipilimumab + nivolumab
• Pembrolizumab
Patients receiving pembrolizumab
• Dabrafenib + trametinib
Dabrafenib + trametinib

Locations

Country	Name	City	State
United States	Novartis Pharmaceuticals	East Hanover	New Jersey

Sponsors (1)

Lead Sponsor	Collaborator
Novartis Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of patients on first systemic adjuvant therapy with adverse avents (AEs)		Up to approximately 5 years
Secondary	Number of patients with AEs following first systemic adjuvant therapy completion/discontinuation.		Up to approximately 5 years
Secondary	Healthcare resource utilization (HCRU) associated with AEs on first systemic adjuvant therapy		Up to approximately 5 years
Secondary	Healthcare costs associated with AEs on first systemic adjuvant therapy		Up to approximately 5 years
Secondary	HCRU associated with AEs following first systemic adjuvant therapy completion/discontinuation		Up to approximately 5 years
Secondary	Healthcare costs associated with AEs following first systemic adjuvant therapy completion/discontinuation		Up to approximately 5 years